One of the most important ways to lessen the effects of the COVID-19 pandemic, which has caused an unprecedented global health crisis, is through vaccination. Despite the controversy surrounding COVID-19 vaccines, Covishield has been India's most popular vaccine. One and a half years after vaccination, this study examines the persistence of antibodies against COVID-19, particularly those produced by Covishield. 350 participants in total, equally split between the sexes, were chosen for this analysis. Serious public health consequences may result from the presence of antibodies years after vaccination. Our results demonstrate the effectiveness of vaccination, as 68% of samples had adequate antibody titers (>0.80 U/mL) against COVID-19. The concurrent emergence of neurological, respiratory, and cardiovascular adverse effects in those who mounted a sufficient antibody response was a noteworthy finding, though. On the other hand, individuals who were unable to produce adequate antibody levels frequently had a significant medical history, indicating that a serious illness could impair the immune response to vaccination. The significance of additional research into the variables influencing antibody development and vaccine effectiveness is underscored by these findings, which show the delicate relationship between vaccine efficacy and individual health status.





